Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Share:
TORONTO, March 11, 2021 (GLOBE NEWSWIRE) Acerus Pharmaceuticals Corporation ( Acerus or the Company ) (TSX:ASP, OTCQB:ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards ( IFRS ).
Recent Highlights
Significant growth in US NATESTO® total prescriptions during the fourth quarter of 2020 – driven by the specialist (urologist and endocrinologist) segment
Rights offering completed in November 2020, strengthening the balance sheet
Shipments of NATESTO® to South Korea and Taiwan resumed in the fourth quarter
The Company entered into an agreement with Torreya Partners LLC to identify strategic options for product acquisition and growth capital
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.
Recent Corporate Updates
Pain Management Franchise
New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results
DUBLIN, Feb. 23, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022 revenues from products launched since 2019, highlighted by the strong execution of our U.S. launches of both Zepzelca and Xywav. Despite the pandemic, we delivered important new treatment options for patients, ensured the well-being of employees and generated significant value for shareholders. We meaningfully increased revenues, executed three product launches, advanced early- and late-stage clinical trials and added multiple new novel product candidates to our expanding pipeline, all of which exemplifies our highly effective operational execution throughout 2020, while continuing our transformation as an inno
Press release content from Business Wire. The AP news staff was not involved in its creation.
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
February 1, 2021 GMT
BOSTON (BUSINESS WIRE) Feb 1, 2021
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provided full-year 2021 financial guidance.
“Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple combination in the U.S. and the EU. It was also a year marked by meaningful pipeline advancement. We now have clinical programs in seven disease areas, spanning multiple modalities including small molecules for alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases, gene editing for sickle cell disease and beta thalassemia, and cell therapy for type 1 diabetes,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Verte